AsiaNet 64287
MELBOURNE, Australia, May 3. 2016/Medianet International-AsiaNet/ --
Gordagen Pharmaceuticals, an Australian private company, today announced positive top-line results of an independent early-phase US clinical study of its nE1-ElitE(TM) sports dietary supplement targeting muscle soreness and function following eccentric exercise.
This study, conducted by a research group from the University of Mount Union, Ohio, sought to confirm Gordagen's existing positive efficacy evidence of its nE1-ElitE(TM) formulation for exercise performance and muscle recovery post exercise. The double-blind, placebo-controlled study showed significant enhancements to recovery from exercise-induced muscle soreness, muscle micro-trauma and weakness.
http://mrem.bernama.com/viewsm.php?idm=26717 |
|
No comments:
Post a Comment